热门站点| 世界资料网 | 专利资料网 | 世界资料网论坛
收藏本站| 设为首页| 首页

Provisions for Import and Export of Anabolic Agents and Peptide Hormones (Interim)

作者:法律资料网 时间:2024-06-16 07:24:53  浏览:9743   来源:法律资料网
下载地址: 点击此处下载

Provisions for Import and Export of Anabolic Agents and Peptide Hormones (Interim)

State Food and Drug Administration General Administration of Customs of the People’s Republic of China


Provisions for Import and Export of Anabolic Agents and Peptide Hormones (Interim)




(SFDA Decree No. 25)

The Provisions for Import and Export of Anabolic Agents and Peptide Hormones (Interim), adopted by the State Food and Drug Administration, the General Administration of Customs of the People’s Republic of China and the General Administration of Sport of China, is hereby promulgated in the decree sequence number of the State Food and Drug Administration and shall come into force as of September 1, 2006.


Shao Mingli
Commissioner
State Food and Drug Administration

Mou Xinsheng
Minister
General Administration of Customs of the People’s Republic of China

Liu Peng
Minister
General Administration of Sport of China
July 28, 2006





Provisions for Import and Export of Anabolic Agents and Peptide Hormones (Interim)


Article 1 The Provisions are formulated with a view to standardizing the administration of import and export of anabolic agents and peptide hormones in accordance with the Drug Administration Law of the People’s Republic of China, Customs Law of People's Republic of China, Anti-doping Regulations and other relevant laws and administrative regulations.

Article 2 The State adopts license control on the import and export of anabolic agents and peptide hormones.

Article 3 The importer shall apply for the importation of anabolic agents and peptide hormones to the State Food and Drug Administration.

Article 4 For the importation of anabolic agents and peptide hormones for medical purpose, the importers shall submit the following materials:
(1) Application Form for Drug Import;
(2) Copy of the purchasing contract or order form;
(3) Copy of the Import Drug License (or the Pharmaceutical Product License) (original or duplicate);
(4) Copy of the Drug Supply Certificate, Business License for Enterprises as a Legal Person, Qualification Certificate for Import and Export Enterprise (or Foreign Trade Operator Filing and Registration Form) and Organization Code Certificate of the importer; to import drug substance and intermediate preparations including preparations to be repackaged in China for their own needs, drug manufacturers shall submit copies of the Drug Manufacturing Certificate, Corporate Business License and Organization Code Certificate;
(5) Where holders of the Import Drug License (or the Pharmaceutical Product License) entrust other companies to export their drugs, they shall provide the authorization letter for export.

All copies mentioned above should be stamped with the official seal of the importer.

Article 5 For the importation of anabolic agents and peptide hormones for teaching and scientific research purposes, the importers shall submit the following materials:
(1) Application Form for Drug Import;
(2) Copy of the purchasing contract or order form;
(3) Certificates of legitimate qualifications of users in China, calculation basis for the quantity of the drug in use and letter of guarantee issued by the user for legitimate use and management of the drug;
(4) Approval documents for relevant scientific research projects or approval documents of relevant competent authority;
(5) Where entrusted by users for importation, importers shall provide copies of the authorization agreement, the Business License for Enterprises as a Legal Person, Qualification Certificate for Import and Export Enterprise (or Foreign Trade Operator Filing and Registration Form) and Organization Code Certificate of the importers.

All copies mentioned above should be stamped with the official seal of the importer.

Article 6 Where a enterprise in China entrusted by an overseas enterprise for contract manufacturing needs to import anabolic agents and peptide hormones, it shall provide materials required in Items (1), (3) and (5) of Paragraph 1 of Article 5, in addition, official documents to prove recorded by the local (food and) drug regulatory department of the province, autonomous region or municipality directly under the Central Government.

All copies mentioned above should be stamped with the official seal of the importer.

Article 7 The State Food and Drug Administration shall decide whether or not to approve the import within 15 working days after receiving the application for import and the relevant materials. Where the application is approved, the State Food and Drug Administration shall issue the Import License for the drug; where the application is not approved, the State Food and Drug Administration shall give reasons in writing.

Article 8 The importer may declare to the customs of the ports where drug importation is permitted upon presenting the Import License for the drug issued by the State Food and Drug Administration. The customs shall clear the drug in the presence of the Import License for the drug.
The Drug Import Note is not required for import of anabolic agents and peptide hormones.

Article 9 To import anabolic agents and peptide hormones including those sold in China for the first time for medical purpose, the importer shall fill in the Import Drug Clearance Form timely after going through the import formalities and submit the following materials in duplicate to the (food and) drug regulatory department where the port of entry is located, upon presenting the original Import Drug License (or the Pharmaceutical Product License) (original or duplicate) and the original Import License for the drug, to apply for the Notice of Import Drug Port Test:
(1) Copies of the Import Drug License (or Pharmaceutical Product License) (original or duplicate) and the Import License for the drug;
(2) Copies of the Drug Manufacturing Certificate or Drug Supply Certificate, and Copy of the Business License for Enterprises as a Legal Person.
(3) Copy of the certificate of origin;
(4) Copy of the purchasing contract;
(5) Copies of packing list, bill of lading and freight invoice;
(6) Copy of the certificate of analysis;
(7) Format of drug insert sheet, package and label (except for drug substance and intermediate preparation);

All copies mentioned above should be stamped with the official seal of the importer.

Article 10 After checking the received Import Drug Clearance Form and relevant materials, the port (food and) drug regulatory department shall return the original Import Drug License (or Pharmaceutical Product License) (original or duplicate) and the original Import License for the drug to the importer, and send the Notice of Import Drug Port Test, along with a copy of the dossier as prescribed in Article 9 of the Provisions, to the port drug testing institute on the same day.

After receiving the Notice of Import Drug Port Test, the port drug testing institute shall contact the importer within two working days and conduct sampling on the storage site. Upon the completion of the sampling, the mark “sampled” shall be stamped on the back of the first page of the original Import License for the drug, with the seal of sampling institute affixed.

Article 11 Anabolic agents and peptide hormones imported for teaching and research purposes or for the domestic manufacturing contracted by overseas enterprises are exempted from testing.

Article 12 The port (food and) drug regulatory department shall report timely to the State Food and Drug Administration in any of the following circumstances:
(1) The port (food and) drug regulatory department refuses to issue the Notice of Import Drug Port Test in accordance with the provisions in Article 17 of the Provisions for Import Drug (Decree No. 4 of the State Food and Drug Administration and the General Administration of Customs);
(2) The port (food and) drug testing institute refuses the sampling in accordance with the requirements in Article 25 of the Provisions for Import Drug.

The port (food and) drug regulatory department shall take mandatory administrative measures to seal up or seize all the imported drugs within the situations prescribed in the previous paragraph. It shall make the decision of allowing shipping back within seven days from the date of the seal-up or seizure, and inform the importer of applying for the Export License for the drug according to the export procedures for anabolic agents and peptide hormones prescribed in the Provisions and return all the import drugs to the original exporting country.

Where the importer fails to respond or make clear its intention to ship back the drugs within ten days after being informed of the decision, the sealed up or seized drugs shall be destroyed under the supervision of the port (food and) drug regulatory department.

Article 13 For imported anabolic agents and peptide hormones out of specifications upon testing by the port drug testing institute, the importer shall provide a detailed report about the distribution and use of all the imported drugs to the port (food and) drug regulatory department where the importer is located within two days after receiving the Import Drug Test Report.

After receiving the Import Drug Test Report, the port (food and) drug regulatory departments shall take mandatory administrative measures to timely seal up or seize all the drugs and, within seven days, decide whether or not to place the case on file.

Where the importer fails to apply for a retesting within the specified timeline or the result of the retesting is still out of specifications, the port (food and) drug regulatory department shall make the decision of allowing shipping back and notify the importer to apply for the Export License for the drug according to export procedures for anabolic agents and peptide hormones prescribed in the Provisions to return all the imported drugs to the original exporting country. Where the importer fails to respond or make clear its intention to ship back the drugs within ten days from the date of receiving the decision, the drugs shall be destroyed under the supervision of the port (food and) drug regulatory department.

Where the result of retesting is in compliance with the specifications, the port (food and) drug regulatory department shall remove the mandatory administrative measures of seal-up and seizure.

The port (food and) drug regulatory department shall handle the case according to the provisions in Paragraph 2, Paragraph 3 and Paragraph 4 of this Article and report the result to the State Food and Drug Administration, and, at the same time, notify the (food and) drug regulatory departments of provinces, autonomous regions and municipalities directly under the Central Government as well as other port (food and) drug regulatory departments.

Article 14 Where domestic drug manufacturers, distributors and medical institutions purchase imported anabolic agents and peptide hormones, the supplier shall provide copies of the Import Drug License (or Pharmaceutical Product License), the Import License for the drug and the Import Drug Test Report, and affix its official seal to the abovementioned copies.

Article 15 The exporter shall apply for exportation of anabolic agents and peptide hormones to the (food and) drug regulatory department of the province, autonomous region or municipality directly under the Central Government, where it is located, and submit the following materials:
(1) Application Form for Drug Export;
(2) Original import permit (or its copy with notarization) provided by the drug regulatory authority of the importing country or region.
If the importing country or region has no license system in the importation of anabolic agents and peptide hormones, the exporter shall provide the official document (original) of the drug regulatory authority of the importing country or region to prove that the import of the drugs of this type is exempted from the import permit, along with one of the following documents:
a. Original official document (or its copy with notarization) granting import provided by the drug regulatory authority of the importing country or region;
b. Certificates of legitimate qualifications of importers and original supporting document (or its copy with notarization) proving legitimate use of the drug;
(3) Copy of the purchasing contract or order form (except for manufacturers that export their own products);
(4) Copy of the export contract or order form;
(5) Where the export drug is an approved one produced by a domestic manufacturer, the Drug Manufacturing Certificate and Business License for Enterprises as a Legal Person of the manufacturer and a copy of the approval document of the drug shall be provided;
Where the export drug is produced by a domestic enterprise under contract of an overseas enterprise, the exporter shall provide a copy of the official document to prove recorded by the local (food and) drug regulatory department of the province, autonomous region and municipality directly under the Central Government.
(6) Copies of the Business License for Enterprises as a Legal Person, Qualification Certificate for Import and Export Enterprise (or Foreign Trade Operator Filing and Registration Form) and Organization Code Certificate of the exporter.

All copies mentioned above should be stamped with the official seal of the exporter.

Article 16 Where the drugs are to be shipped back in accordance with the requirements in Article 12 and Article 13 of the Provisions, the exporter shall provide the following materials to apply for the Export License for the drug:
(1) Documents proving the request for return of goods made by the original exporter of the exporting country;
(2) Import License for the drug.

Article 17 The (food and) drug regulatory department of the province, autonomous region and municipality directly under the Central Government shall decide whether or not to approve the export within 15 working days after receiving the export application and relevant materials.

Where the application is approved, the regulatory department shall issue the Export License for the drug; where the application is not approved, the regulatory department shall give reasons in writing.

Where the Export License for the drug is applied for in accordance with the requirements in Article 16 of the Provisions, the issuing authority shall mark “return of the original goods” on the Export License for the drug.

Article 18 The exporter may go through the customs formalities upon presenting the Export License for the drug issued by the (food and) drug regulatory department of the province, autonomous region and municipality directly under the Central Government. The customs shall clear the drug in the presence of the Export License for the drug.

Article 19 The importer and exporter shall provide one more sheet of customs declaration form and apply for sign-back of the sheet when going through the customs formalities. The customs shall stamp the “proof seal” on the sheet in the presence of the Import License for the drug and Export License for the drug. The customs shall charge the cost according to the relevant regulations for issuing certificates.

The importer and exporter shall return the first sheet of the Import License for the drug or Export License for the drug along with the customs declaration form with the seal of the customs, to the issuing regulatory department within one month after completing the import and export.

Where the importer or exporter conducts no relevant importation or exportation after obtaining the Import License for the drug and Export License for the drug, the importer or exporter shall return the original license to the issuing regulatory department within one month after expiration of the license.

Article 20 The validation of the Import License for the drug is one year; the validation of the Export License for the drug is no more than three months (valid within the calendar year).

“One license for one customs clearance” is implemented for the Import License for the drug and Export License for the drug. The license shall be used only once within the validation and its content shall not be altered. Where the import or export is postponed for some reasons, the importer or exporter may request for a new license once with the original one.

Article 21 Where the Import License for the drug or Export License for the drug is lost, the importer or exporter shall report the loss to the original issuing authority in writing immediately. After receiving the loss report, the original issuing authority shall notify the port customs and reissue the license if no harmful consequences are found through confirmation.

Article 22 The Import License for the drug and Export License for the drug are uniformly printed by the State Food and Drug Administration.

Article 23 Where anabolic agents and peptide hormones are imported or exported in the form of processing trade, the customs shall go through and supervise the clearance formalities upon presentation of the Import License for the drug or Export License for the drug. Those not exported for special reasons shall be transferred to and handled by the local (food and) drug regulatory department in accordance with relevant regulations, and the customs shall conduct the verification and cancellation procedures in the presence of relevant documents.

Article 24 Anabolic agents and peptide hormones entering or leaving between bonded zones, export processing zones, other special Customs controlling areas, Customs bonded and controlling areas, with overseas, or between the special Customs controlling areas and the Customs bonded and controlling areas are exempt from application for the Import License for the drug or Export License for the drug, and supervised by the Customs.

Import License for the drug shall be applied for anabolic agents and peptide hormones entering from bonded zones, export processing zones, other special Customs controlling areas and Customs bonded and controlling areas into other places in China.

Export License for the drug shall be applied for anabolic agents and peptide hormones entering bonded zones, export processing zones, other special Customs controlling areas and Customs bonded and controlling areas from other places of China.

Article 25 Where an individual carries or mails anabolic agents and peptide hormones, within a reasonable amount, into or out of China for medical needs, the customs shall clear the drugs in the presence of prescriptions of medical institutions in accordance with relevant regulations on prescriptions of the competent health department.

Article 26 Besides prescribed in the Provisions, the importation, port test, supervision and control of anabolic agents and peptide hormones for medical purpose are implemented with reference to requirements related to drug importation in the Provisions for Drug Importation.

Article 27 Anabolic agents and peptide hormones imported for medical purpose mentioned in the Provisions refer to the import anabolic agents and peptide hormones to be used for preparation production or to be marketed in China.

Importer refers to the importer specified on the Import License for the drug obtained in accordance with the Provisions.

Exporter refers to the exporter specified on the Export License for the drug obtained in accordance with the Provisions.

Article 28 These Provisions shall go into effect as of September 1, 2006. The Notice on Import and Export of Anabolic Agents and Peptide Hormones (Guo Shi Yao Jian An [2004] No. 474) issued by the State Food and Drug Administration on September 30, 2004 shall be annulled therefrom.


下载地址: 点击此处下载

深圳市财政局、深圳市贸易工业局关于印发《深圳市产业技术进步资金管理暂行办法》的通知

广东省深圳市财政局、深圳市贸易工业局


深圳市财政局、深圳市贸易工业局关于印发《深圳市产业技术进步资金管理暂行办法》的通知
(2005年10月12日)

深财企〔2005〕40号

   为加强产业技术进步资金的管理,提高资金使用效率,保证资金使用的公开、公平和公正,根据财政部《关于印发产业技术研究与开发资金管理办法的通知》(财建〔2002〕30号)、市政府《印发关于依靠技术进步推动深圳工业持续快速发展的若干措施的通知》(深府〔1999〕47号)的有关规定,我们制定了《深圳市产业技术进步资金管理暂行办法》。现予印发,请遵照执行。

深圳市产业技术进步资金管理暂行办法

第一章 总则

   第一条为加强产业技术进步资金的管理,提高资金使用效率,保证资金使用的公开、公平和公正,根据财政部《关于印发产业技术研究与开发资金管理办法的通知》(财建〔2002〕30号)、市政府《印发关于依靠技术进步推动深圳工业持续快速发展的若干措施的通知》(深府〔1999〕47号)的有关规定,制定本办法。
   第二条本办法所称产业技术进步资金(以下称专项资金),是指市政府每年从财政预算安排的为鼓励支持企业利用新技术、新工艺,扩大生产规模、提高产品质量、开发新的品种以及市政府批准的促进我市经济结构调整和产业结构优化升级政策而设立的专项资金。
   第三条专项资金的管理和使用应坚持公开、公平、公正的原则,实行自愿申报、专家评审、社会公示、科学决策和绩效评价制度。

第二章 管理职责及分工

   第四条市工业主管部门的职责如下:
   (一)向市财政部门提出年度专项资金预算;
   (二)编制年度专项资金决算;
   (三)受理项目申请、组织项目考察、评审、招标等;
   (四)会同市财政部门制订重点扶持企业标准并确定企业名单;
   (五)按照有关规定下达专项资金计划;
   (六)负责项目验收,跟踪、检查资金使用和项目实施情况,开展项目绩效评价;
   (七)制定与本办法配套的有关实施细则和操作规程。
   第五条市财政部门的职责如下:
   (一)审核安排年度专项资金预算;
   (二)确定年度专项资金支出结构;
   (三)审查年度专项资金决算;
   (四)参与制订重点扶持企业标准并确定企业名单、下达资金计划、制定与本办法配套的有关实施细则和操作规程;
   (五)办理资金拨款,监督检查资金使用情况,负责资金使用绩效评价。
   第六条符合本办法规定条件的项目单位,应当按照有关规定履行下列职责:
   (一)制定项目投资预算,负责项目实施和配套资金;
   (二)对项目资金进行财务管理和会计核算;
   (三)接受有关部门的监督检查和验收;
   (四)按要求提供项目执行情况的报告及附属材料。

第三章 资助对象、资助方式及支出结构

   第七条 专项资金资助对象:在深圳注册的,且主要生产经营活动在深圳的企业及为企业提供服务的各类机构。
   第八条 专项资金采取补贴、奖励、贴息、借款等四种资助方式。
   第九条 专项资金的60%以上用于经有关部门确认的重点扶持企业、公共技术平台等建设项目。
   贴息应占年度安排资金总量的20%以上。
   借款和补贴的资金比例应达到6∶4。

第四章 资助条件及标准

   第十条 以补贴方式资助的项目包括:公共技术服务平台、企业技术中心、企业信息化建设重点项目及示范项目、产业集聚基地规划。
   公共技术服务平台建设补贴:按《深圳市工业行业公共技术平台管理暂行办法》执行,并根据公共技术服务平台的建设规模确定补贴金额。
   企业技术中心建设补贴:按《深圳市工业企业技术中心认定和考核办法》及《关于进一步量化深圳市企业技术中心认定指标的通知》执行。市级企业技术中心的补贴标准统一为每家300万元人民币;国家级企业技术中心的补贴标准统一为每家500万元人民币。
   企业信息化建设重点项目补贴:按《深圳市企业信息化重点项目扶持办法》执行。每个试点项目扶持配套资金总额原则上最高不超过150万元;每个试点平台扶持配套资金总额原则上最高不超过200万元。
   产业集聚基地补贴:列入市政府关于产业集聚基地建设计划的项目单位可申请规划费补贴。具体补贴金额按基地建设规模另行确定。
   第十一条 获得“中国名牌产品”、“中国驰名商标”称号的企业,按照市政府的有关规定奖励。
   第十二条 以贴息方式资助的项目主要是技术改造项目。该项目应当通过国家或市工业主管部门核准或备案,且项目的建设主体和实施地均在深圳市。
   取得用于项目建设的固定资产贷款并实际发生了利息支付,经过工业主管部门委托专业中介机构对项目进展及资金投入情况进行审计,可申请贴息支持,贴息最高期限不超过两年,同一企业年度获得贴息总额原则上最高不超过600万元。
   项目竣工并完成验收后,才能申请足额贴息。
   第十三条 申请企业技术改造借款的项目应当在国家或市工业主管部门办理项目核准或备案,且项目建设条件已基本落实,项目承担单位经营正常,财务状况良好,具备较强还款能力。
   被列入深圳市重点扶持企业名单的可获得1000万元(含1000万元)以下的借款;其它企业可获得500万元(含500万元)以下借款。借款期限原则上为2年,最长不超过3年。

第五章 资助申报及审批

   第十四条 市工业主管部门应当制定公共技术服务平台和企业技术中心建设规划,报市政府批准后实施。
   市工业主管部门提出年度资金预算,市财政部门审核制订年度资金支出结构意见,报分管工业的市长审批后执行。
   第十五条 补贴、借款项目申请常年受理,贴息申请每年集中办理一至二次。
   (一)补贴项目:由市工业主管部门进行考察,组织评审,或委托中介机构进行专项审计。符合条件的,市工业主管部门提出资金计划,经市财政部门复核后,在有关媒体上公示,公示期为5个工作日。公示后无异议的,由上述两部门联合下达资金计划,市工业主管部门和资金使用单位签定资金使用合同,市财政部门办理拨款手续。
   (二)借款项目:由市工业主管部门审查项目资料,确定推荐企业名单,由受托机构评审项目,决定是否发放借款,并将同意放款的项目清单报市工业主管部门。市工业主管部门下达项目计划并抄送市财政部门,项目单位与受托机构办理借款手续。
   (三)贴息项目:市工业主管部门委托中介机构对项目的投入及付息情况进行审计,并提出贴息计划,经市财政部门复核同意后,联合下达贴息资金计划,财政部门办理拨款手续。
   (四)奖励:市工业主管部门根据我市企业当年在“中国名牌产品”、“中国驰名商标”评选结果提出奖励计划,市财政部门复核后,报市政府批准,办理拨款手续。

第六章 资金使用及项目管理

   第十六条获得补贴的项目单位必须在监管银行开立专户,专款专用。
   第十七条公共技术服务平台和企业技术中心补贴资金只能用于购置设备、软件及服务,企业信息化补贴只能用于购置设备、软件,支付信息化系统维护费用及网络使用费用。
   符合政府采购条例规定的,应按规定办理政府采购。
   第十八条 项目单位收到补贴资金,贷记“专项应付款”科目,专项资金形成固定资产的,经项目竣工验收后结转到“资本公积—拨款转入”科目。
   项目单位收到贴息资金的,直接冲减财务费用。
   项目单位收到奖励资金,贷记“补贴收入”科目。
   第十九条 项目单位必须按照报送的项目资金投入计划使用资金,实际资金使用计划调整超过总投资20%的及时报告市工业主管部门。
   第二十条 市工业主管部门应与项目单位签定补贴资金使用合同,并对补贴资金的使用和项目的进度进行跟踪管理。资金使用超出范围,市工业主管部门可授权监管银行拒付。
   监管银行由市财政部门负责确定并定期考核。
   第二十一条 资助项目因故取消、因不可抗力原因无法继续实施,或继续实施已无必要时,项目单位应及时向市工业主管部门申报项目终止。经市工业主管部门部门组织审计后,剩余专项资金由市财政部门收回。
   第二十二条项目单位应当在项目竣工后3个月内向市工业主管部门提交项目竣工验收报告并提出竣工验收申请。
   项目总贴息额低于100万元的项目,由市工业主管部门委托会计师事务所进行竣工专项审计;项目总贴息金额100万元及以上的项目,除了开展竣工专项审计外,还应当组织专家现场验收。
   第二十三条 当年回收的专项资金,可结转以后年度使用。   

第七章 监督检查

  第二十四条市工业主管部门对专项资金的使用进行日常跟踪管理,对项目的实施进行绩效评价,并及时向分管市领导报告,同时抄送市财政部门。项目绩效评价结果将作为审查申请人再次申请资助资格的依据。
   市财政部门对专项资金管理和使用情况进行重点监督检查,并开展整体绩效评价。
   第二十五条 对于违反财经纪律,虚报、冒领、截留、挪用、挤占专项资金的行为,由市财政部门责令改正,同时按照《财政违法行为处罚处分条例》规定的权限由市财政、审计、监察机关进行处理、处分或处罚。构成犯罪的,依法追究刑事责任。
   对存在上款违规行为的单位,市工业主管部门3年内不受理资助申请。
   第二十六条受委托的社会中介机构在项目和经费的评审、评估和审计过程中,存在弄虚作假、隐瞒事实真相、与资助资金申请单位串通作弊等行为并出具相关报告的,由市工业主管部门取消其项目和经费的评审、评估和审计资格,同时依法追究相关单位和责任人的法律责任。
   第二十七条参与评审、评估的专家利用评审、评估机会以权谋私或弄虚作假的,取消咨询专家资格,并由有关部门依法追究其相应责任。构成犯罪的,依法追究刑事责任。
   第二十八条专项资金管理工作人员违反本办法,不认真履行职责,与项目单位人员串通、弄虚作假,或利用职务之便,收受他人好处的,由市财政和监察机关等按照《财政违法行为处罚处分条例》、《深圳市行政机关工作人员行政过错责任追究暂行办法》规定的权限对责任人进行处理。构成犯罪的,依法移交司法机关处理。

第八章 附则

   第二十九条专项资金的管理费用按照有关规定列入部门年度预算。
   第三十条本办法自发布之日起实施。原《深圳市产业技术进步资金管理办法》(深财企〔2002〕15号)同时废止。

吉林省联合经营合同暂行规定

吉林省人民政府


吉林省联合经营合同暂行规定
吉林省人民政府


第一章 总 则
第一条 为保护联合经营合同当事人的合法权益,维护社会经济秩序,促进横向经济联合健康发展,根据国家有关法律、法规的规定,结合我省实际情况,制定本暂行规定。
第二条 联合经营合同是指法人之间为从事生产或经营,在人才、技术、资金、资源、工业产权等方面进行联合而订立的相互间权利、义务关系的协议(以下简称联营合同)。
第三条 订立联营合同必须贯彻自愿平等、协商一致、互利互惠、共担风验、共享利益的原则。
订立联营合同,必须采用书面形式。联合各方协商同意的有关修改联营合同的文书(包括电报和图表)均是联营合同的组成部分。
第四条 订立联营合同必须遵守国家法律、法规,必须符合国家政策和计划的要求,任何单位和个人都不得利用联营合同进行违法活动,损害国家利益和社会公共利益。
第五条 联营合同依法成立,即具有法律约束力,当事人必须全面履行合同规定的义务,任何一方不得擅自变更或解除。
第六条 本暂行规定适用于吉林省境内法人之间及吉林省境内法人与省外法人之间,为进行各种形式的联合而订立的联营合同。
第七条 各级工商行政管理部门是联营合同的主管机关,统一管理联营合同(负责监督联营合同的订立和履行,确认无效联营合同,查处利用联营合同进行违法活动的行为,仲裁联营合同纠纷等)。

第二章 联营合同的订立、变更和解除
第八条 订立联营合同前,当事人应对联营项目及其经济效益进行可行性论证,并制订联营章程。
第九条 联营合同应依照联营章程由联营各方的法定代表人或其授权的委托代理人签订,并加盖法人印章。
第十条 紧密型联合经营经济组织的联营合同应具备以下主要条款:
(一)联营项目、生产经营范围、生产经营规模、生产经营方式:
(二)投资形式、投资总额、各方出资比例及出资额、交付期限、资金来源。
(三)以非资金形式投入的联营合同标的价值确定方法;
(四)联营各方的收益分配和亏损承担的比例及支付方式、支讨期限;
(五)联营合同变更和解除的条件、程序及经济责任;
(六)违约责任及违约金、赔偿金的计算方法、支付方式和支付期限;
(七)联营合同的生效条件和有效期限;
(八)联营经济组织终止时的财产清结、审计方法及程序,债权债务的分担、清偿方式;
(九)联营各方当事人根据有关法律规定必须具备或共同商定的其他条款。
第十一条 签订半紧密型、松散型联合经营经济组织的联营合同,参照紧密型联合经营经济组织联营合同的条款办理。
第十二条 联营合同的任何一方当事人要求对方提供保证的,可由自愿保证的单位担保。被保证单位不履行合同的,保证单位负连带责任。
第十三条 凡有下列情况之一者,允许变更或解除联营合同:
(一)合同内容违反国家法律、法规、政策和计划的;
(二)当事人一方没有履行合同能力的;
(三)当事人一方违反合同规定,使合同履行成为不必要的;
(四)当事人一方因关闭、停产、转产或破产使合同确实无法履行的;
(五)订立联营合同所依据的国家计划修改或取消的;
(六)由于不可抗力或当事人一方虽无过失但无法防止的外因,致使合同无法履行的;
(七)各方当事人经过协商同意,并且不因此损害国家利益和影响国家计划执行的。
第十四条 当事人一方要求变更或解除联营合同时,应及时通知他方;因变更或解除合同使他方遭受损失的,除依法可以免除责任的外,应由责任方负责赔偿损失。
当事人一方合并、分立时,由变更后的当事人承担或分别承提履行合同的义务或享受应有的权利。

第三章 违反联营合同的责任
第十五条 联营合同当事人任何一方违约的,应该向他方支付违约金。如果由于违约给他方造成的损失超过违约金的,应支付赔偿金,以补偿违约金不足部分。他方要求继续履行合同的,应继续履行。
第十六条 凡有下列行为之一者,应负违反联营合同的责任:
(一)联营一方逾期缴付投资款的;
(二)以非资金形式投入的联营合同标的不符合联营合同规定的;
(三)以工业产权参加联营,未按有关规定和合同的约定办理转让及使用手续的;
(四)联营一方未按合同的约定使用工业产权,非法转让或造成泄密的;
(五)联营一方未按合同规定生产,致使产品质量不合格的;
(六)联营一方擅自退出联营组织或转让投资的;
(七)违反联营合同的其他约定事项的。
第十七条 凡具有第十六条中第一项、第二项、第三项、第七项所规定的违约行为之一者,除联营合同另有约定者外,由违约方向他方支付其投资额1-5%的违约金;凡具有第十六条中第四项、第五项、第六项所规定的违约行为之一者,除联营合同另有约定者处,由违约方向他方支
付联营投资额3-8%的违约金。
第十八条 逾期支付违约金、赔偿金按《中华人民共和国经济合同法》及有关规定办理。
第十九条 由于上级领导机关或业务主管部门的过错,造成违约的,上级领导机关或业务主管部门承担违约责任。但须先由违约方按规定向他方偿付违约金或赔偿金,再由应负责任的上级领导机关或业务主管部门负责处理。
第二十条 当事人一方由于不可抗力的原因不能履行联营合同时,应及时向对方通报不能履行、不能完全履行或者需要延期履行的理由,在取得有关主管机关证明后,允许延期履行、部分履行或不履行合同,并根据情况部分或全部免予承担违约责任。

第四章 联营合同的管理
第二十一条 联营合同的当事人应服从工商行政管理部门有关履行联营合同的检查和监督。
第二十二条 无效联营合同的确认权,归工商行政管理机关和人民法院。
第二十三条 对于当事人订立假联营合同或利用联营合同进行危害国家利益和社会公共利益的违法行为,工商行政管理机关可视其情节,进行批评教育,给予没收非法所得、罚款、吊销营业执照等处罚;对构成犯罪的,由司法机关依法追究刑事责任。
第二十四条 联营合同发生纠纷时,当事人各方应及时协商解决;协商不成时,任何一方都可向有管辖权的经济合同仲裁机关申请调解仲裁,也可以向人民法院起诉。

第五章 附 则
第二十五条 本省境内的私营企业、个体工商户、农村承包户及公民与法人之间订立的联营合同参照本暂行规定执行。
第二十六条 本暂行规定与国家有关规定相抵触时,按国家规定执行。
第二十七条 本暂行规定自发布之日起施行。



1988年6月28日

版权声明:所有资料均为作者提供或网友推荐收集整理而来,仅供爱好者学习和研究使用,版权归原作者所有。
如本站内容有侵犯您的合法权益,请和我们取得联系,我们将立即改正或删除。
京ICP备14017250号-1